<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" article-type="research-article"><?properties manuscript?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-journal-id">101242667</journal-id><journal-id journal-id-type="pubmed-jr-id">32627</journal-id><journal-id journal-id-type="nlm-ta">Sex Health</journal-id><journal-id journal-id-type="iso-abbrev">Sex Health</journal-id><journal-title-group><journal-title>Sexual health</journal-title></journal-title-group><issn pub-type="ppub">1448-5028</issn><issn pub-type="epub">1449-8987</issn></journal-meta><article-meta><article-id pub-id-type="pmid">34183114</article-id><article-id pub-id-type="pmc">8457403</article-id><article-id pub-id-type="doi">10.1071/SH20185</article-id><article-id pub-id-type="manuscript">NIHMS1735992</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Hepatitis B prevalence association with sexually transmitted
infections: A systematic review and meta-analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Marseille</surname><given-names>Elliot</given-names></name><degrees>DrPH, MPP</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Harris</surname><given-names>Aaron M.</given-names></name><degrees>MD, MPH</degrees><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Horvath</surname><given-names>Hacsi</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Parriott</surname><given-names>Andrea</given-names></name><degrees>MPH, PhD</degrees><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Malekinejad</surname><given-names>Mohsen</given-names></name><degrees>MD, DrPH</degrees><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Nelson</surname><given-names>Noele P.</given-names></name><degrees>MD, PhD, MPH</degrees><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Van Handel</surname><given-names>Michelle</given-names></name><degrees>MPH</degrees><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kahn</surname><given-names>James G.</given-names></name><degrees>MD, MPH</degrees><xref ref-type="aff" rid="A3">3</xref></contrib></contrib-group><aff id="A1"><label>1</label>Health Strategies International</aff><aff id="A2"><label>2</label>U.S. Centers for Disease Control and Prevention; Division
of Viral Hepatitis</aff><aff id="A3"><label>3</label>Philip R. Lee Institute for Health Policy Studies, Global
Health Sciences, and Global Health Economics Consortium, University of California,
San Francisco</aff><aff id="A4"><label>4</label>Philip R. Lee Institute for Health Policy Studies and
Consortium to Assess Prevention Economics, University of California, San
Francisco</aff><aff id="A5"><label>5</label>Philip R. Lee Institute for Health Policy Studies, Global
Health Sciences and Consortium to Assess Prevention Economics, University of
California, San Francisco</aff><author-notes><corresp id="CR1">Address correspondence to Michelle Van Handel, MPH, U.S. Centers
for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30333; Ph:
404-639-0947; <email>mvanhandel@cdc.gov</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>9</day><month>9</month><year>2021</year></pub-date><pub-date pub-type="ppub"><month>7</month><year>2021</year></pub-date><pub-date pub-type="pmc-release"><day>22</day><month>9</month><year>2021</year></pub-date><volume>18</volume><issue>3</issue><fpage>269</fpage><lpage>279</lpage><!--elocation-id from pubmed: 10.1071/SH20185--><abstract id="ABS1"><sec id="S1"><title>Background.</title><p id="P1">Hepatitis B vaccination is recommended for persons with current or
past sexually transmitted infections (STI). Our aim is to systematically
assess the association of hepatitis B virus (HBV) sero-markers for current
or past infection with syphilis, chlamydia, gonorrhea, or unspecified
STIs.</p></sec><sec id="S2"><title>Methods.</title><p id="P2">We conducted a systematic review and meta-analysis. PubMed, Embase,
and Web of Science from 1982 &#x02013;2018 were searched using MeSH terms for
HBV, STIs and epidemiology. We included studies conducted in Organization
for Economic Cooperation and Development countries or Latin America that
permit the calculation of prevalence ratios (PRs) for HBV and STIs and
extracted PRs and counts by HBV and STI status.</p></sec><sec id="S3"><title>Results.</title><p id="P3">Of 3,144 identified studies, 43 met inclusion requirements, yielding
72 PRs. We stratified outcomes by HBV sero-markers (surface antigen [HBsAg],
core antigen [anti-HBc], combined ), STI pathogen (syphilis,
gonorrhea/chlamydia, unspecified), and STI history (current, past) resulting
in 18 potential outcome groups, for which results were available for 14. For
the four outcome groups related to HBsAg, PR point estimates ranged from
1.65 &#x02013; 6.76. For the five outcome groups related to anti-HBc, PRs
ranged from 1.30 &#x02013; 1.82; and for the five outcome groups related to
combined HBV markers, PRs ranged from 1.15 &#x02013; 1.89). The median HBsAg
prevalence among people with a current or past STI was 4.17; not all studies
reported HBsAg. Study settings and populations varied.</p></sec><sec id="S4"><title>Conclusion.</title><p id="P4">This review found evidence of association between HBV infection and
current or past STIs.</p></sec></abstract><abstract id="ABS2" abstract-type="summary"><title>Summary:</title><p id="P5">Chronic hepatitis B virus (HBV) infection is a major source of morbidity
and mortality in the United States and the most common source of HBV infection
among adults is sexual contact. We conducted a comprehensive systematic review
and meta-analysis of the association of hepatitis B prevalence among persons
with current and past sexually transmitted infection and found the prevalence of
hepatitis B significantly associated with sexually transmitted infection. These
findings can inform potential recommendations for expanded hepatitis B
testing.</p></abstract><kwd-group><kwd>systematic review</kwd><kwd>meta-analysis</kwd><kwd>hepatitis B</kwd><kwd>sexually transmitted infections</kwd><kwd>gonorrhea</kwd><kwd>chlamydia</kwd><kwd>syphilis</kwd></kwd-group></article-meta></front><body><sec id="S5"><title>Introduction</title><p id="P6">Chronic hepatitis B virus (HBV) infection is a major source of morbidity and
mortality worldwide. An estimated 257 million persons worldwide are chronically
infected with HBV, which results in approximately 887,000 deaths annually (<xref rid="R1" ref-type="bibr">1</xref>). In the United States, 847,000 persons were
living with the disease in 2011&#x02013;2012 (<xref rid="R2" ref-type="bibr">2</xref>) and 1,698 deaths were attributed to HBV in 2016 (<xref rid="R3" ref-type="bibr">3</xref>). About two-thirds of persons with chronic HBV
infection were unaware of their infection, and an estimated 15% of
treatment-eligible patients are receiving treatment (<xref rid="R4" ref-type="bibr">4</xref>, <xref rid="R5" ref-type="bibr">5</xref>).</p><p id="P7">Chronic HBV infection is defined as the presence of hepatitis B surface
antigen (HBsAg) for more than 6 months. Prevalence is highest among persons born in
the Pacific Islands, Asia and Africa (<xref rid="R2" ref-type="bibr">2</xref>, <xref rid="R6" ref-type="bibr">6</xref>). Other high-burden populations include men
who have sex with men (MSM), persons who inject drugs (PWID), persons who have been
incarcerated, and sexual and household contacts of persons with HBV infection (<xref rid="R7" ref-type="bibr">7</xref>). The Centers for Disease Control and
Prevention (CDC) recommends screening for hepatitis B among person at risk; however
current guidelines do not include testing persons with a history of STI (<xref rid="R8" ref-type="bibr">8</xref>).</p><p id="P8">Since both sexually transmitted infections (STI) and HBV infections can be
transmitted through unprotected sexual contact, persons with current or past STI are
at elevated risk for HBV infection. As a result, CDC recommends hepatitis B
vaccination in adults seeking evaluation or treatment for STIs (<xref rid="R9" ref-type="bibr">9</xref>). While CDC does not recommend pre-vaccination testing
for persons with current or past STI, the American Association for the Study of
Liver Disease recommends hepatitis B testing for these persons (<xref rid="R10" ref-type="bibr">10</xref>), and the American College of Physicians recommends
hepatitis B testing for persons with a history of STI as a best practice (<xref rid="R7" ref-type="bibr">7</xref>). Hepatitis B is commonly transmitted through
sexual contact (<xref rid="R11" ref-type="bibr">11</xref>); however, the hepatitis B
prevalence among persons with current or past STI is unknown. We report the
association of hepatitis B prevalence among persons with current and past STI
through a comprehensive systematic review and meta-analysis.</p></sec><sec id="S6"><title>Methods</title><p id="P9">Our methods are based on recommendations of the Cochrane Collaboration (<xref rid="R12" ref-type="bibr">12</xref>), and reporting is consistent with Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and
checklist; details available in <xref rid="SD1" ref-type="supplementary-material">Appendix A</xref> (<xref rid="R13" ref-type="bibr">13</xref>).</p><sec id="S7"><title>Data sources and searches.</title><p id="P10">We searched PubMed, Embase and Web of Science, employing terms from
Medical Subject Headings (MeSH) relevant to HBV infection, STIs and
epidemiology. We reviewed the literature between 1982, when the first HBV
vaccine was approved, and our search date of March 18, 2018. Search terms and
strategy are shown in <xref rid="SD1" ref-type="supplementary-material">Appendix
B</xref>.</p></sec><sec id="S8"><title>Study selection.</title><p id="P11">To be included, studies needed to report prevalence of hepatitis B and
past or current syphilis, gonorrhea/chlamydia or unspecified STIs, from any of
the 36 high-income countries of the Organization for Economic Co-operation and
Development (OECD) or a Latin American country. In addition, they either needed
to provide measures of association such as odds ratios (ORs) or prevalence
ratios (PRs) or provide data on HBV prevalence in both STI-exposed (past or
current STI) and STI-unexposed (no past or current STI) sub-groups, from which
PRs could be derived. Randomized controlled trials, prospective or retrospective
observational cohorts, serial cross-sectional studies, and other longitudinal
analyses published in any language were eligible for inclusion. Studies in
peer-reviewed journals, reports from scientific conferences, and doctoral
dissertations were eligible for inclusion. Studies in languages other than
English were assessed by translating key passages into English using Google
Translate. HBV infection could be defined as positive surface antigen (HBsAg) or
as core antibody detection (anti-HBc), and we stratified results according to
these two types of markers. We also included studies that combined HBV marker
types without specifying which, surface antigen or core antibody, was used to
define HBV infection. STI prevalence data could reflect current or past
infections. Studies were excluded if they focused on persons with HIV or
immigrant populations.</p></sec><sec id="S9"><title>Data synthesis and analysis.</title><p id="P12">We used PRs as the measure of association between HBV infection and
STIs. In addition to the few studies that provided PRs (or risk ratios)
directly, studies were included if PRs could be constructed from the reported
data. When adjusted measures were provided, typically as ORs, we used adjusted
measures rather than crude measures. However, when adjusted measures were not
reported, but data were available to construct unadjusted PRs from 2 &#x000d7; 2
data we did so, using Open-Epi&#x02019;s 2 &#x000d7; 2 table function (<xref rid="R14" ref-type="bibr">14</xref>). &#x0201c;2 &#x000d7; 2 data&#x0201d;
refers to the number of HBV negative and HBV positive cases for both STI
negative and STI positive groups. We used 2 &#x000d7; 2 data even if unadjusted
ORs were available in order to keep consistent and precise methods. We converted
both adjusted ORs and unadjusted ORs when 2 &#x000d7; 2 data were unavailable to
PRs using the formula suggested by Zhang and Yu (<xref rid="R15" ref-type="bibr">15</xref>), <disp-formula id="FD1"><mml:math display="block" id="M1"><mml:mi>PR</mml:mi><mml:mo>=</mml:mo><mml:mi>OR</mml:mi><mml:mo>/</mml:mo><mml:mo>(</mml:mo><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>)</mml:mo><mml:mo>+</mml:mo><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">&#x000d7;</mml:mi><mml:mspace width="0.25em"/><mml:mi>OR</mml:mi><mml:mo>)</mml:mo><mml:mo>)</mml:mo></mml:math></disp-formula> where, P<sub>0</sub> is the prevalence of the outcome of
interest (HBV-positivity) in the unexposed group (STI-negative).</p><p id="P13">We used Comprehensive Meta Analysis&#x02122; (Version 3.3, Englewood, New
Jersey) software to perform the meta-analysis. We used a random effects model
because included studies were diverse in design, setting, and population (<xref rid="R16" ref-type="bibr">16</xref>).</p><p id="P14">Hepatitis B screening should include HBsAg, antibody to HBsAg
(anti-HBs), and anti-HBc so that patients can be categorized into clinical
states for appropriate management (<xref rid="R7" ref-type="bibr">7</xref>). Our
methods divided HBV serological markers because not all the studies included
results of all 3 serologic markers. Therefore, we defined 18 meta-analyses
strata, <italic>a priori,</italic> according to three variables that would
likely affect the association of HBV infection and STI, as well as the clinical
care for persons with HBV infection or STI, as follows: HBV markers (three
groups: HBsAg, anti-HBc, combined), STI type (three groups: syphilis, gonorrhea
or chlamydia [treated as one group], unspecified), and STI history (two groups:
current or past). We used funnel plots to visually explore the relationship
between the log of the pooled PR and their associated standard errors. To
portray study heterogeneity, we reported the Iota-square statistic and its
p-value for each pooled outcome (<xref rid="R17" ref-type="bibr">17</xref>,
<xref rid="R18" ref-type="bibr">18</xref>).</p></sec><sec id="S10"><title>Data extraction and quality assessment.</title><p id="P15">We imported records resulting from our search into EndNote&#x02122;
(Version X8, Pittsburgh, PA). One reviewer removed duplicate records. After
removing duplicate records, a reviewer performed an initial review to exclude
citations that were clearly irrelevant (e.g., different disease), and then
screened citation titles, abstracts and keywords of the remaining citations to
identify records for full-text review. The lead author conducted quality
assessment by sampling 50% of the excluded records to ensure no systematic
exclusion of eligible studies. The full text of each screened-in article was
obtained and then reviewed by the lead author to establish final relevance of
the study according to the pre-specified inclusion criteria. Reasons for
exclusion were recorded, such as no prevalence ratio reported or calculable from
the available data, or the study pertained to a migrant population. The lead
author extracted the measures of association as descried in the <xref rid="S9" ref-type="sec">data synthesis and analysis</xref> section. Data were
extracted into a database maintained in Microsoft Excel&#x02122; (Version Office
365, Redmond, Washington). A senior statistician and study co-author checked all
calculations to ensure that the numbers were extracted, interpreted and
calculated properly. For the risk of bias assessment, the Quality Assessment
Tool for Observation Cohort and Cross-sectional Studies was used since only
observational studies were identified (<xref rid="R19" ref-type="bibr">19</xref>). Two reviewers independently evaluated study quality and differences
were resolved by a third reviewer to determine the adequacy of study population
selection and recruitment, outcome and exposure measurement and assessment, and
statistical analyses, relative to other observational studies, using (<xref rid="SD1" ref-type="supplementary-material">Appendix C</xref>).</p></sec></sec><sec id="S11"><title>Results</title><sec id="S12"><title>Search results.</title><p id="P16">Our searches yielded 3,144 unique citations, including 1,740 from
PubMed, 235 from Embase and 1,169 from Web of Science, yielding 2,114 citations
after removal of duplicates. (<xref rid="F1" ref-type="fig">Figure 1</xref>).
Screening of titles and abstracts identified 329 citations for full text review,
of which 43 met inclusion criteria and were advanced to data extraction and
inclusion in the meta-analysis. Key information on the 43 included studies is
shown in <xref rid="T1" ref-type="table">Table 1</xref>.</p><p id="P17">Classifying studies by HBV marker type, we included nine studies
reporting prevalence by surface antigen (HBsAg) positivity providing 13 PRs; 19
studies reporting core antibody (anti-HBc) prevalence providing 37 PRs; and 18
studies that did not identify which HBV marker was used providing 25 PRs. Thus,
a total of 75 PRs were included in the meta-analysis from a total of 43 studies.
Three studies (Carmo 2014, Hennessey 2009, and van Duynhoven 1997) provided data
on both HBsAg and anti-HBc (<xref rid="R20" ref-type="bibr">20</xref>&#x02013;<xref rid="R22" ref-type="bibr">22</xref>). Thus, the
number of studies shown in <xref rid="SD1" ref-type="supplementary-material">Appendix D</xref>, 72, differs from the number of PRs, 75. Nearly half
(47.9%) of the PRs reported associations with syphilis, 12.9% reported
associations with chlamydia or gonorrhea, and 39.2% reported associations with
unspecified STI. Of the 72 PRs, 38 (52.8%) were unadjusted and 34 were adjusted,
typically by basic demographics such as age and sex. By geographical
classification, PRs were divided between OECD countries excluding the U.S.
(24.0%), the U.S. (37.5%), and Latin America (38.5%). (See <xref rid="SD1" ref-type="supplementary-material">Appendix D</xref>)</p></sec><sec id="S13"><title>Hepatitis B prevalence among persons with STIs.</title><p id="P18">Among the 13 PRs that incorporated HBsAg, we derived 11 values for
hepatitis B prevalence among persons with STIs finding that the median
prevalence 4.17%, and ranged from 0.91% (95% CI: 0.60, 1.37%) among first-time
blood donors in the U.S. for current syphilis (<xref rid="R23" ref-type="bibr">23</xref>) to 33.2% (95% CI: 27.4%, 39.0%) among MSM in the U.S. for
current unspecified STIs (<xref rid="R24" ref-type="bibr">24</xref>). See <xref rid="T1" ref-type="table">Table 1</xref>.</p></sec><sec id="S14"><title>Meta-analysis results.</title><p id="P19">Overall, we found positive and statistically significant associations
between HBV infection and STI prevalence in 12 of the 14 strata for which we
were able to calculate pooled PRs. None of the pooled results showed negative
associations between HBV infection and STIs. Specific results grouped by HBV
marker are presented below:</p><sec id="S15"><title>Surface antigen (HBsAg) as the marker for HBV-positivity</title><p id="P20">We reported four data points (two pooled and two based on a single
study) for the association of STI and HBV infection for studies using HBsAg
as the marker for HBV-positivity. Of these, three showed statistically
significant associations: past syphilis (k=1, PR 2.36, 95% CI: 1.36, 4.08),
current syphilis (k=6, PR 6.76, 95% CI: 2.10, 21.76), (<xref rid="F2" ref-type="fig">Figure 2</xref>) and past unspecified STIs (k=5, PR 1.65,
95% CI: 1.08, 2.52), (See <xref rid="F3" ref-type="fig">Figure 3</xref> in
<xref rid="SD1" ref-type="supplementary-material">web appendix</xref>).
The result for current chlamydia / gonorrhea showed a positive but
statistically insignificant association (k=1, PR 2.00, 95% CI: 0.93, 4.32).
(See <xref rid="F4" ref-type="fig">Figure 4</xref> in <xref rid="SD1" ref-type="supplementary-material">web appendix</xref>). (Note that these
figures do not always match the results shown in <xref rid="SD1" ref-type="supplementary-material">Appendix E</xref>, as the latter
displays unadjusted outcomes only). We observed high heterogeneity
(I<sup>2</sup> 73.6% and 91.4%) in the two analyses for which
heterogeneity could be assessed.</p></sec><sec id="S16"><title>Core antibody (anti-HBc) as the marker for HBV-positivity</title><p id="P21">We reported five pooled data outcomes for the association of STI and
HBV infection for studies using anti-HBc as the marker for HBV-positivity.
All showed statistically significant associations: past syphilis (k=6, PR
1.48, 95% CI: 1.10, 1.99), current syphilis (k=7, PR 1.82, 95% CI: 1.60,
2.06), past chlamydia / gonorrhea, (k=8, PR 1.30, 95% CI: 1.02, 1.66), and
past and current unspecified STIs, (k=12, PR 1.62, 95% CI: 1.31, 1.99) and
(k=4, PR1.42, 95% CI: 1.23, 1.63), respectively. The result for current
unspecified STIs showed moderate heterogeneity, (I<sup>2</sup> 42.4%). The
other four outcomes had high heterogeneity with I<sup>2</sup> ranging from
83.8% - 97.6%</p></sec><sec id="S17"><title>Combined surface antigen (HBsAg) or core antibody (anti-HBc) as the
marker for HBV-positivity</title><p id="P22">We reported five pooled outcomes for the association of STI and HBV
infection for studies that combined HBV marker types. Three of these showed
statistically significant associations: current syphilis (k=7, PR 1.69, 95%
CI: 1.39, 2.07), past chlamydia / gonorrhea, (k=2, PR 1.73, 95% CI: 1.48,
2.01), and past and unspecified STIs (k=8, PR 1.89, 95% CI: 1.52, 2.37). The
pooled outcomes for past syphilis and current chlamydia / gonorrhea were not
statistically significant (k=3, PR 1.51, 95% CI: 0.89, 1.52) and (k=2, PR
1.15, 95% CI: 0.77, 1.62), respectively. The result showed high
heterogeneity for current and past syphilis (I<sup>2</sup> 95 &#x02013; 96%),
moderate heterogeneity for unspecified STI (I<sup>2</sup> 45%), and low
heterogeneity for current and past chlamydia / gonorrhea (I<sup>2</sup> 0% -
15%). See <xref rid="T2" ref-type="table">Table 2</xref> below.</p></sec></sec><sec id="S18"><title>Sensitivity analysis.</title><p id="P23">Gilson 1998 used a different measure of STI prevalence than the other
studies, namely &#x0003c;2 versus &#x02265;2 lifetime episodes (<xref rid="R25" ref-type="bibr">25</xref>). If this study is removed, the pooled PR for the
association between anti-HBc and past unspecified STIs is 1.43 (CI 1.23&#x02013;
1.67) versus 1.62 (CI 1.31&#x02013;1.99) when Gilson 1998 is included.</p><p id="P24">The majority (88%) of studies had an overall study quality rating of
fair relative to other observational studies (<xref rid="SD1" ref-type="supplementary-material">Appendix C</xref>). No studies had an
overall quality rating of poor, and thus no sensitivity analyses were conducted
to assess impact of excluding studies with a poor quality rating. However, there
was noted variability identified for statistical adjustment for potential
confounding variables. In order to understand the effect that a mix of adjusted
and unadjusted measures may have had on our results, we ran the analysis using
unadjusted measures only. Of the 11 pooled PRs that were statistically
significant in the full data set, two lost their statistical significance (the
association between HBsAg and unspecified past STIs, and between anti-HBc and
unspecified current STIs). See <xref rid="SD1" ref-type="supplementary-material">Appendix E</xref>.</p></sec></sec><sec id="S19"><title>Discussion</title><p id="P25">We undertook a systematic review and meta-analysis of the relationship
between HBV infection and current or past STIs. We found a substantial body of
evidence suggesting that there are positive and statistically significant
associations between the prevalence of hepatitis B and STIs in the mix of countries,
settings, and subpopulations for which we found usable studies. HBsAg prevalence
among persons with STIs were derived from 11 of the 13 outcomes available for
studies specifically reporting HBsAg prevalence with a median value of 4.17% and a
range of 0.91% to 33.20% depending on the population, setting, and infection
pathogen.</p><p id="P26">Among adults in the United States, the most common route of transmission for
hepatitis B virus is sexual contact Among the 26% of persons with case-reports of
acute HBV infection with information about risk behaviors or exposures, 22.9%
reported having two or more sexual partners, 6.5% reported sexual contact with an
HBV-infected person, and 12.2% of males reported having sex with another male (<xref rid="R26" ref-type="bibr">26</xref>). As many as 10%&#x02212;40% of adults
seeking treatment in STI clinics have evidence of current or past HBV infection, and
39% were screened or sought care for an STI prior to becoming infected with HBV
(<xref rid="R27" ref-type="bibr">27</xref>). As a result, CDC recommends
vaccination of adults at risk for HBV infection including persons at risk for
infection by sexual exposure (<xref rid="R28" ref-type="bibr">28</xref>).</p><p id="P27">CDC does not currently recommend pre-vaccination serologic testing for HBV
among persons with current or a history of STI (<xref rid="R9" ref-type="bibr">9</xref>), although the American Association for the Study of Liver Disease has
recommended testing this group since 2009 (<xref rid="R10" ref-type="bibr">10</xref>). HBV infection and STI share common modes of transmission, and hepatitis
B can be transmitted by sexual exposure. Transmission also occurs by close
person-to-person contact by open cuts and sores, in hyperendemic areas (<xref rid="R28" ref-type="bibr">28</xref>). Therefore, persons with STI are likely at
increased risk of HBV infection and should be vaccinated, and considered for
pre-vaccination serologic testing (<xref rid="R29" ref-type="bibr">29</xref>).
Screening, linkage to care, and vaccination programs for adults at risk for
hepatitis B are a best practice (<xref rid="R6" ref-type="bibr">6</xref>). Our
review suggests high hepatitis B prevalence among persons with current or past STI.
As a result of this higher hepatitis B prevalence, person with a history of STI
could benefit by receiving hepatitis B vaccination if they are negative or be linked
to life saving care and treatment if they are found to be positive. In addition,
those who are identified as positive can be counseled and is an opportunity to
disrupt transmission of the virus to others.</p><p id="P28">While there was a large range of values for HBV infection and STI prevalence
in the populations included in this review, the range of prevalence ratios is much
more constrained. The pooled estimates vary from 1.65 to 6.76 for HBsAg, from 1.30
to 1.82 for anti-HBc and 1.15 to 1.89 unspecified HBsAg / anti-HBc. This suggests
that, given a known prevalence of STIs within a potential target population, one
might make reasonably precise estimates of the yield of HBV-positive persons.</p><p id="P29">We observed an overall clustering of effect sizes around the top of all
three funnels reflecting the preponderance of large studies. This observation
suggests that smaller studies could have been excluded. However, there is no reason
to think that this exclusion was due to the magnitude or direction of their
association. In addition, any potential exclusion of such studies is unlikely to
affect the pooled effect sizes. For one of the three plots, we observed a few effect
sizes on the right side of the plot but not on the left side at the bottom of the
funnel; in addition to risk of publication bias, data heterogeneity chance, and
other reasons may explain this asymmetry (<xref rid="R17" ref-type="bibr">17</xref>). (See <xref rid="SD1" ref-type="supplementary-material">Appendix
F</xref>).</p><p id="P30">Among the strengths of this paper are its comprehensive look at the range of
relevant HBV markers and STIs combined with a sufficiently large number of outcomes
to test for statistical significance within each stratum. Thus, we were able to
group &#x02018;like with like&#x02019; and still obtain, for most pooled estimates, a
fairly narrow confidence interval. The results were robust to sensitivity analyses
in which a study with a different approach to portraying STI outcomes was omitted,
and to confining the analyses to unadjusted outcomes only.</p><p id="P31">However, there are limitations to the methods employed in this study. We
confined our literature search to PubMed, Embase and the Web of Science data bases,
and did not exhaustively review the grey literature. It is thus possible that we
excluded relevant information that may have affected findings. Because there are no
other published systematic reviews pertaining to our research question, it is not
possible to compare our results against those of other investigators who might have
used different methods. As in all systematic reviews, we evaluated only studies that
met inclusion criteria. Broader criteria, such as acceptance of earlier studies, or
a different geographic or economic specification of included countries, might have
yielded a different result, although the inclusion / exclusion criteria used are
appropriate to the research question we addressed.</p><p id="P32">Given the existence of contextual heterogeneity (i.e., variation in
population, study design, outcome reporting metrics) and statistical heterogeneity,
we used random effects. Thus, the pooled point estimates provide an overall average
effect size that may not be accurate for specific target populations and settings.
Therefore, in addition to point estimates, confidence intervals should be taken into
considerations for decision-making pertaining to disease screening programs or
modeling. Given the cross-sectional nature of most of studies and the fact that both
types of infections share common risk factors, we only assessed their association,
not causal relationships. Related, during the quality assessment, we did not reduce
the overall quality rating for studies that did not measure exposures prior to the
outcome of interest since it would not be ethical in most instances to delay an
effective vaccination in order to monitor outcomes overtime.</p><p id="P33">We derived PRs from adjusted measures of association when available and thus
have a mix of adjusted and unadjusted PRs, Sensitivity analyses suggests this is not
a major issue. Not all studies included HBsAg, which may have limited our
estimations of the association between STI and infectious HBV. Including studies
that reported on HBsAg or anti-HBc markers but did not specify which was used to
determine hepatitis B status introduces an element of ambiguity in the
interpretation of that sub-set of findings. However, these findings are consistent
with findings pertaining to the known HBV marker types. Removing these results does
not affect our overall findings. Even if we stratified data by HBV markers and STI
pathogens, there is still a high degree of heterogeneity in some of the pooled
analyses. This suggests that factors other than those for which we stratified may
explain the heterogeneity.</p></sec><sec id="S20"><title>Conclusion</title><p id="P34">This systematic review and meta-analysis found a substantial body of
evidence suggesting robust and statistically significant associations between the
prevalence of HBV infection and STIs for multiple infections and using various
serologic tests. These findings may be useful in better understanding the potential
benefits of pre-vaccination serologic testing for HBV among persons with or at risk
for STIs and framing potential recommendations for expanded hepatitis B testing.</p></sec><sec sec-type="supplementary-material" id="SM1"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Appendices</label><media xlink:href="NIHMS1735992-supplement-Appendices.docx" orientation="portrait" id="d40e467" position="anchor"/></supplementary-material></sec></body><back><ack id="S21"><title>Funding.</title><p id="P35">This project was completed with funding from CAPE (Consortium for Assessment
of Prevention Economics), of the NCHHSTP Epidemiological and Economic Modeling
Agreement (Grant No: U38PS004649), with the Centers for Disease Control and
Prevention. Its contents are solely the responsibility of the authors. The findings
and conclusions in this report are those of the authors and do not necessarily
represent the official position of the Centers for Disease Control and
Prevention.</p><p id="P36"><bold>Funding source:</bold> U.S. Centers for Disease Control and
Prevention</p></ack><fn-group><fn fn-type="COI-statement" id="FN1"><p id="P37">Compliance with Ethical Standards</p><p id="P38"><bold>Disclosure of potential conflicts of interest.</bold> The authors
declare that they have no conflict of interest.</p></fn><fn id="FN2"><p id="P39"><bold>Research involving Human Participants and/or Animals.</bold> This
article does not contain any studies with human participants or animals
performed by any of the authors.</p></fn><fn id="FN3"><p id="P40"><bold>Informed consent.</bold> As no human subjects were involved in the
research undertaken to produce this article, no informed consent was
required.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1.</label><mixed-citation publication-type="web"><collab>World Health Organization</collab>.
<source>Hepatitis B</source>
<comment>[updated July 27, 2020];</comment>
<date-in-citation>cited 2021</date-in-citation>. <comment>Available from
<ext-link ext-link-type="uri" xlink:href="https://www.who.int/news-room/fact-sheets/detail/hepatitis-b">https://www.who.int/news-room/fact-sheets/detail/hepatitis-b</ext-link>.</comment></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><name><surname>Roberts</surname><given-names>H</given-names></name>, <name><surname>Kruszon-Moran</surname><given-names>D</given-names></name>, <name><surname>Ly</surname><given-names>KN</given-names></name>, <etal/><article-title>Prevalence of chronic hepatitis B virus (HBV) infection in U.S.
households: National Health and Nutrition Examination Survey (NHANES),
1988&#x02013;2012</article-title>. <source>Hepatology</source><year>2016</year>;<volume>63</volume>(<issue>2</issue>):<fpage>388</fpage>&#x02013;<lpage>97</lpage>.
doi: <pub-id pub-id-type="doi">10.1002/hep.28109</pub-id>
[<comment>published Online First: 2015/08/08</comment>]<pub-id pub-id-type="pmid">26251317</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><collab>Center for Disease Control and
Prevention</collab>. <source>Surveillance for Viral Hepatitis &#x02013;
United States, 2016</source>.
<year>2016</year>:<fpage>75</fpage>.</mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><name><surname>Lin</surname><given-names>SY</given-names></name>, <name><surname>Chang</surname><given-names>ET</given-names></name>, <name><surname>So</surname><given-names>SK</given-names></name>. <article-title>Why we should routinely screen Asian American adults for
hepatitis B: a cross-sectional study of Asians in
California</article-title>. <source>Hepatology</source><year>2007</year>;<volume>46</volume>(<issue>4</issue>):<fpage>1034</fpage>&#x02013;<lpage>40</lpage>.
doi: <pub-id pub-id-type="doi">10.1002/hep.21784</pub-id>
[<comment>published Online First: 2007/07/27</comment>]<pub-id pub-id-type="pmid">17654490</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><name><surname>Cohen</surname><given-names>C</given-names></name>, <name><surname>Holmberg</surname><given-names>SD</given-names></name>, <name><surname>McMahon</surname><given-names>BJ</given-names></name>, <etal/><article-title>Is chronic hepatitis B being undertreated in the United
States?</article-title><source>Journal of viral hepatitis</source><year>2011</year>;<volume>18</volume>(<issue>6</issue>):<fpage>377</fpage>&#x02013;<lpage>83</lpage>.
doi: <pub-id pub-id-type="doi">10.1111/j.1365-2893.2010.01401.x</pub-id>
[<comment>published Online First: 2010/12/15</comment>]<pub-id pub-id-type="pmid">21143343</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><name><surname>Mitchell</surname><given-names>T</given-names></name>, <name><surname>Armstrong</surname><given-names>GL</given-names></name>, <name><surname>Hu</surname><given-names>DJ</given-names></name>, <etal/><article-title>The increasing burden of imported chronic hepatitis B--United
States, 1974&#x02013;2008</article-title>. <source>PloS one</source><year>2011</year>;<volume>6</volume>(<issue>12</issue>):<fpage>e27717</fpage>.
doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0027717</pub-id> [<comment>published
Online First: 2011/12/14</comment>]<pub-id pub-id-type="pmid">22163270</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><name><surname>Abara</surname><given-names>WE</given-names></name>, <name><surname>Qaseem</surname><given-names>A</given-names></name>, <name><surname>Schillie</surname><given-names>S</given-names></name>, <etal/><article-title>Hepatitis B Vaccination, Screening, and Linkage to Care: Best
Practice Advice From the American College of Physicians and the Centers for
Disease Control and Prevention</article-title>. <source>Annals of internal
medicine</source><year>2017</year>;<volume>167</volume>(<issue>11</issue>):<fpage>794</fpage>&#x02013;<lpage>804</lpage>.
doi: <pub-id pub-id-type="doi">10.7326/M17-1106</pub-id>
[<comment>published Online First: 2017/11/22</comment>]<pub-id pub-id-type="pmid">29159414</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><name><surname>Weinbaum</surname><given-names>CM</given-names></name>, <name><surname>Williams</surname><given-names>I</given-names></name>, <name><surname>Mast</surname><given-names>EE</given-names></name>, <etal/><article-title>Recommendations for identification and public health management
of persons with chronic hepatitis B virus infection</article-title>.
<source>MMWR Recomm Rep</source>
<year>2008</year>;<volume>57</volume>(<issue>RR-8</issue>):<fpage>1</fpage>&#x02013;<lpage>20</lpage>.
[<comment>published Online First: 2008/09/20</comment>]</mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><name><surname>Schillie</surname><given-names>S</given-names></name>, <name><surname>Vellozzi</surname><given-names>C</given-names></name>, <name><surname>Reingold</surname><given-names>A</given-names></name>, <etal/><article-title>Prevention of Hepatitis B Virus Infection in the United States:
Recommendations of the Advisory Committee on Immunization
Practices</article-title>. <source>MMWR Recomm Rep</source><year>2018</year>;<volume>67</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>31</lpage>.
doi: <pub-id pub-id-type="doi">10.15585/mmwr.rr6701a1</pub-id>
[<comment>published Online First: 2018/06/26</comment>]</mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><name><surname>Lok</surname><given-names>AS</given-names></name>, <name><surname>McMahon</surname><given-names>BJ</given-names></name>. <article-title>Chronic hepatitis B</article-title>.
<source>Hepatology</source>
<year>2007</year>;<volume>45</volume>(<issue>2</issue>):<fpage>507</fpage>&#x02013;<lpage>39</lpage>.
doi: <pub-id pub-id-type="doi">10.1002/hep.21513</pub-id>
[<comment>published Online First: 2007/01/30</comment>]<pub-id pub-id-type="pmid">17256718</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><name><surname>Roberts</surname><given-names>H</given-names></name>, <name><surname>Jiles</surname><given-names>R</given-names></name>, <name><surname>Harris</surname><given-names>AM</given-names></name>, <name><surname>Gupta</surname><given-names>N</given-names></name>, <name><surname>Teshale</surname><given-names>E</given-names></name>. <article-title>Incidence and Prevalence of Sexually Transmitted
Hepatitis B, United States, 2013&#x02013;2018</article-title>. <source>Sex
Trans Dis</source><year>2021</year>. doi: <pub-id pub-id-type="doi">10.1097/OLQ.0000000000001359</pub-id> [<comment>published
Online First: 2021/01/23</comment>]</mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><name><surname>Higgins</surname><given-names>JPT</given-names></name>, <name><surname>Green</surname><given-names>S</given-names></name>. <article-title>Cochrane Handbook for Systematic Reviews of
Interventions</article-title>. <source>5.1.0 ed: The Cochrane
Collaboration</source><year>2011</year>.</mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><name><surname>Moher</surname><given-names>D</given-names></name>, <name><surname>Liberati</surname><given-names>A</given-names></name>, <name><surname>Tetzlaff</surname><given-names>J</given-names></name>, <etal/><article-title>Preferred reporting items for systematic reviews and
meta-analyses: the PRISMA statement</article-title>. <source>British Medical
Journal</source><year>2009</year>;<volume>339</volume>:<fpage>b2535</fpage>. doi:
<pub-id pub-id-type="doi">10.1136/bmj.b2535</pub-id><pub-id pub-id-type="pmid">19622551</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><collab>OpenEpi</collab>:
<article-title>Open Source Epidemiologic Statistics for Public Health,
[program]</article-title>. <source>Version 3.01 -- Released April 4 and
revised April 6, 2013 version</source>, <year>2013</year>.</mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>J</given-names></name>, <name><surname>Yu</surname><given-names>KF</given-names></name>. <article-title>What&#x02019;s the relative risk? A method of correcting
the odds ratio in cohort studies of common outcomes</article-title>.
<source>JAMA : the journal of the American Medical Association</source>
<year>1998</year>;<volume>280</volume>(<issue>19</issue>):<fpage>1690</fpage>&#x02013;<lpage>1</lpage>.<pub-id pub-id-type="pmid">9832001</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="book"><name><surname>Borenstein</surname><given-names>M</given-names></name>. <source>Introduction to meta-analysis</source>.
<publisher-loc>Chichester, U.K.</publisher-loc>: <publisher-name>John Wiley
&#x00026; Sons</publisher-name>
<year>2009</year>.</mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="book"><name><surname>Higgins Julian</surname><given-names>PT</given-names></name>, <name><surname>Saly</surname><given-names>Green</given-names></name>, editors. <source>Cochrane Handbook for Systematic Reviews of
Interventions Version 5.0.2 [updated September 2009]</source>.
<publisher-name>The Cochrane Collaboration</publisher-name>,
<year>2009</year>.</mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><name><surname>Higgins</surname><given-names>JP</given-names></name>, <name><surname>Thompson</surname><given-names>SG</given-names></name>, <name><surname>Deeks</surname><given-names>JJ</given-names></name>, <etal/><article-title>Measuring inconsistency in meta-analyses</article-title>.
<source>Bmj</source>
<year>2003</year>;<volume>327</volume>(<issue>7414</issue>):<fpage>557</fpage>&#x02013;<lpage>60</lpage>.
doi: <pub-id pub-id-type="doi">10.1136/bmj.327.7414.557</pub-id> [<comment>published
Online First: 2003/09/06</comment>]<pub-id pub-id-type="pmid">12958120</pub-id></mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="web"><collab>National Institutes of Health
&#x02013; National Heart, Lung, and Blood Institute</collab>. <source>Study
Quality Assessment Tools &#x02013; Quality Assessment Tool for Observational
Cohort and Cross-Sectional Studies</source>; <date-in-citation>cited
2021</date-in-citation>. <comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools">https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools</ext-link>.</comment></mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><name><surname>van Duynhoven</surname><given-names>YT</given-names></name>, <name><surname>van de Laar</surname><given-names>MJ</given-names></name>, <name><surname>Schop</surname><given-names>WA</given-names></name>, <etal/><article-title>Prevalence and risk factors for hepatitis B virus infections
among visitors to an STD clinic</article-title>. <source>Genitourin
Med</source><year>1997</year>;<volume>73</volume>(<issue>6</issue>):<fpage>488</fpage>&#x02013;<lpage>92</lpage>.
[<comment>published Online First: 1998/05/16</comment>]<pub-id pub-id-type="pmid">9582467</pub-id></mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><name><surname>Hennessey</surname><given-names>KA</given-names></name>, <name><surname>Kim</surname><given-names>AA</given-names></name>, <name><surname>Griffin</surname><given-names>V</given-names></name>, <etal/><article-title>Prevalence of infection with hepatitis B and C viruses and
co-infection with HIV in three jails: a case for viral hepatitis prevention
in jails in the United States</article-title>. <source>J Urban
Health</source><year>2009</year>;<volume>86</volume>(<issue>1</issue>):<fpage>93</fpage>&#x02013;<lpage>105</lpage>.
doi: <pub-id pub-id-type="doi">10.1007/s11524-008-9305-8</pub-id> [<comment>published
Online First: 2008/07/16</comment>]</mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><name><surname>Carmo</surname><given-names>RA</given-names></name>, <name><surname>Melo</surname><given-names>AP</given-names></name>, <name><surname>Dezanet</surname><given-names>LN</given-names></name>, <etal/><article-title>Correlates of hepatitis B among patients with mental illness in
Brazil</article-title>. <source>Gen Hosp Psychiatry</source><year>2014</year>;<volume>36</volume>(<issue>4</issue>):<fpage>398</fpage>&#x02013;<lpage>405</lpage>.
doi: <pub-id pub-id-type="doi">10.1016/j.genhosppsych.2014.03.001</pub-id>
[<comment>published Online First: 2014/04/15</comment>]<pub-id pub-id-type="pmid">24725973</pub-id></mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><name><surname>Zou</surname><given-names>S</given-names></name>, <name><surname>Notari</surname><given-names>EP</given-names></name>, <name><surname>Fang</surname><given-names>CT</given-names></name>, <etal/><article-title>Current value of serologic test for syphilis as a surrogate
marker for blood-borne viral infections among blood donors in the United
States</article-title>. <source>Transfusion</source><year>2009</year>;<volume>49</volume>(<issue>4</issue>):<fpage>655</fpage>&#x02013;<lpage>61</lpage>.
doi: <pub-id pub-id-type="doi">10.1111/j.1537-2995.2008.02042.x</pub-id>
[<comment>published Online First: 2009/01/28</comment>]<pub-id pub-id-type="pmid">19170999</pub-id></mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><name><surname>Weinbaum</surname><given-names>CM</given-names></name>, <name><surname>Lyerla</surname><given-names>R</given-names></name>, <name><surname>Mackellar</surname><given-names>DA</given-names></name>, <etal/><article-title>The Young Men&#x02019;s Survey phase II: hepatitis B immunization
and infection among young men who have sex with men</article-title>.
<source>Am J Public Health</source>
<year>2008</year>;<volume>98</volume>(<issue>5</issue>):<fpage>839</fpage>&#x02013;<lpage>45</lpage>.
doi: <pub-id pub-id-type="doi">10.2105/AJPH.2006.101915</pub-id> [<comment>published
Online First: 2008/04/03</comment>]<pub-id pub-id-type="pmid">18382012</pub-id></mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><name><surname>Gilson</surname><given-names>RJ</given-names></name>, <name><surname>de Ruiter</surname><given-names>A</given-names></name>, <name><surname>Waite</surname><given-names>J</given-names></name>, <etal/><article-title>Hepatitis B virus infection in patients attending a genitourinary
medicine clinic: risk factors and vaccine coverage</article-title>.
<source>Sex Transm Infect</source>
<year>1998</year>;<volume>74</volume>(<issue>2</issue>):<fpage>110</fpage>&#x02013;<lpage>5</lpage>.
[<comment>published Online First: 1998/06/20</comment>]<pub-id pub-id-type="pmid">9634322</pub-id></mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="web"><collab>CDC</collab>. <source>Surveillance
for Acute Viral Hepatitis &#x02014; United States, 2018 Atlanta, GA</source>.
[<date-in-citation>updated July 27, 2020</date-in-citation>].
<comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/hepatitis/statistics/2018surveillance/index.htm">https://www.cdc.gov/hepatitis/statistics/2018surveillance/index.htm</ext-link></comment></mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><collab>CDC</collab>. <source>Viral
hepatitis-statistics and surveillance</source>. <year>2015</year><comment>[updated September 26, 2017];</comment><date-in-citation>cited 2018</date-in-citation>. <comment>Available from:
<ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/hepatitis/populations/stds.htm">https://www.cdc.gov/hepatitis/populations/stds.htm</ext-link>.</comment></mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><name><surname>Mast</surname><given-names>EE</given-names></name>, <name><surname>Margolis</surname><given-names>HS</given-names></name>, <name><surname>Fiore</surname><given-names>AE</given-names></name>, <etal/><article-title>A comprehensive immunization strategy to eliminate transmission
of hepatitis B virus infection in the United States: recommendations of the
Advisory Committee on Immunization Practices (ACIP) part 1: immunization of
infants, children, and adolescents</article-title>. <source>MMWR Recomm
Rep</source><year>2005</year>;<volume>54</volume>(<issue>RR-16</issue>):<fpage>1</fpage>&#x02013;<lpage>31</lpage>.
[<comment>published Online First: 2005/12/24</comment>]</mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><name><surname>Lok</surname><given-names>AS</given-names></name>, <name><surname>McMahon</surname><given-names>BJ</given-names></name>. <article-title>Chronic hepatitis B: update 2009</article-title>.
<source>Hepatology</source>
<year>2009</year>;<volume>50</volume>(<issue>3</issue>):<fpage>661</fpage>&#x02013;<lpage>2</lpage>.
doi: <pub-id pub-id-type="doi">10.1002/hep.23190</pub-id>
[<comment>published Online First: 2009/08/29</comment>]<pub-id pub-id-type="pmid">19714720</pub-id></mixed-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Figure 1:</label><caption><p id="P41">Flowchart for systematic review<sup><xref rid="P42" ref-type="other">1</xref></sup></p><p id="P42"><sup>1</sup>From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA
Group (2009). Preferred Reporting Items for Systematic Reviews and
Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:<ext-link ext-link-type="doi" xlink:href="10.1371/journal.pmed1000097">10.1371/journal.pmed1000097</ext-link></p><p id="P43">2. Three studies contributed outcomes to two HBV marker types</p></caption><graphic xlink:href="nihms-1735992-f0001"/></fig><fig id="F2" orientation="portrait" position="float"><label>Figure 2.</label><caption><p id="P44">Forest plot - Association between HBsAg and past and current
syphilis.</p></caption><graphic xlink:href="nihms-1735992-f0002"/></fig><fig id="F3" orientation="portrait" position="float"><label>Figure 3.</label><caption><p id="P45">Forest plot - Association between HBsAg and past unspecified STIs.</p></caption><graphic xlink:href="nihms-1735992-f0003"/></fig><fig id="F4" orientation="portrait" position="float"><label>Figure 4.</label><caption><p id="P46">Forest plot - Association between HBsAg and current gonorrhea</p></caption><graphic xlink:href="nihms-1735992-f0004"/></fig><table-wrap id="T1" position="float" orientation="landscape"><label>Table 1.</label><caption><p id="P47">Characteristics of 43 studies included in calculation of association
between HBV infections and STIs</p></caption><table frame="box" rules="all"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><tbody><tr><td colspan="9" align="left" valign="top" rowspan="1">&#x02003;<bold><italic>A. Studies
using surface antigen (HbsAg) as HBV marker</italic></bold></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td colspan="2" align="center" valign="top" rowspan="1">
<bold>Hepatitis B prevalence
(%)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="center" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td rowspan="2" align="center" valign="top" colspan="1">
<bold>STI-negatives</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>STI-positives</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Prevalence
ratios</bold>
<sup><bold>1</bold></sup>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">
<bold>Author, Pub., Year</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>Country</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>Setting</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>Quality rating</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>Population</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>STI measure</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>Point est, (Low -High 95%
CI)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>N, point est., (Low-High 95%
CI)</bold>
</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Carmo, Gen Hosp Psychiatry,
2014</td><td rowspan="2" align="center" valign="top" colspan="1">Brazil</td><td rowspan="2" align="left" valign="top" colspan="1">26 public mental health
services</td><td rowspan="2" align="left" valign="top" colspan="1">Fair</td><td rowspan="2" align="left" valign="top" colspan="1">Randomly selected adults with
mental illness under care</td><td align="center" valign="top" rowspan="1" colspan="1">Past STIs</td><td rowspan="2" align="center" valign="top" colspan="1">2.00</td><td align="center" valign="top" rowspan="1" colspan="1">1.92, (NR)</td><td align="center" valign="top" rowspan="1" colspan="1">2176, 0.93, (0.66&#x02013;1.36)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Past syphilis</td><td align="center" valign="top" rowspan="1" colspan="1">4.17, (NR)</td><td align="center" valign="top" rowspan="1" colspan="1">2140, 2.36, (1.36&#x02013;4.07)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hart, Sex Transm Dis, 1993</td><td align="center" valign="top" rowspan="1" colspan="1">Australia</td><td align="left" valign="top" rowspan="1" colspan="1">STI clinic, Adelaide</td><td align="left" valign="top" rowspan="1" colspan="1">Fair</td><td align="left" valign="top" rowspan="1" colspan="1">All attendees during study period -
Females</td><td align="center" valign="top" rowspan="1" colspan="1">Current gonorrhea</td><td align="center" valign="top" rowspan="1" colspan="1">7.10</td><td align="center" valign="top" rowspan="1" colspan="1">NR</td><td align="center" valign="top" rowspan="1" colspan="1">3998, 2.00, (0.90&#x02013;4.20)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hennessey, Urban Health, 2009</td><td align="center" valign="top" rowspan="1" colspan="1">USA</td><td align="left" valign="top" rowspan="1" colspan="1">Jail - Chicago, Detroit, S.F.</td><td align="left" valign="top" rowspan="1" colspan="1">Fair</td><td align="left" valign="top" rowspan="1" colspan="1">Incoming jail inmates (M + F)</td><td align="center" valign="top" rowspan="1" colspan="1">Current syphilis</td><td align="center" valign="top" rowspan="1" colspan="1">0.90</td><td align="center" valign="top" rowspan="1" colspan="1">2.00, (0.40&#x02013;3.70)</td><td align="center" valign="top" rowspan="1" colspan="1">11165, 6.02, (2.30&#x02013;14.94)</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Miranda, Sex Transm Dis.,
2001</td><td rowspan="2" align="center" valign="top" colspan="1">Brazil</td><td rowspan="2" align="left" valign="top" colspan="1">Antenatal clinics in Vitoria
Municipality</td><td rowspan="2" align="left" valign="top" colspan="1">Fair</td><td rowspan="2" align="left" valign="top" colspan="1">Pregnant women</td><td align="center" valign="top" rowspan="1" colspan="1">Past STIs</td><td rowspan="2" align="center" valign="top" colspan="1">0.80</td><td align="center" valign="top" rowspan="1" colspan="1">NR</td><td align="center" valign="top" rowspan="1" colspan="1">1608, 1.00, (0.13&#x02013;7.15)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Current syphilis</td><td align="center" valign="top" rowspan="1" colspan="1">10.42 (4.09&#x02013;22.61)</td><td align="center" valign="top" rowspan="1" colspan="1">1608, 12.50, (4.64&#x02013;33.66)</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Parazzini, Genitourin
Med.,1992</td><td rowspan="2" align="center" valign="top" colspan="1">Italy</td><td rowspan="2" align="left" valign="top" colspan="1">Two STI clinics</td><td rowspan="2" align="left" valign="top" colspan="1">Fair</td><td rowspan="2" align="left" valign="top" colspan="1">Patients who referred themselves
to clinic for suspected STD or STD treatment</td><td align="center" valign="top" rowspan="1" colspan="1">Current syphilis - TPHA</td><td align="center" valign="top" rowspan="1" colspan="1">7.80</td><td align="center" valign="top" rowspan="1" colspan="1">15.06 (8.45&#x02013;25.18)</td><td align="center" valign="top" rowspan="1" colspan="1">588, 1.55, (0.81&#x02013;3.59)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Current syphilis - VDRL</td><td align="center" valign="top" rowspan="1" colspan="1">6.90</td><td align="center" valign="top" rowspan="1" colspan="1">9.09 (3.91&#x02013;18.78)</td><td align="center" valign="top" rowspan="1" colspan="1">588, 0.91, (0.31&#x02013;2.21)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Souto, Mem Inst Oswaldo Cruz., 2001</td><td align="center" valign="top" rowspan="1" colspan="1">Brazil</td><td align="left" valign="top" rowspan="1" colspan="1">Area comprising 16 gold mine camps in Apiacas
county</td><td align="left" valign="top" rowspan="1" colspan="1">Fair</td><td align="left" valign="top" rowspan="1" colspan="1">Malaria-exposed gold Miners</td><td align="center" valign="top" rowspan="1" colspan="1">Past STIs</td><td align="center" valign="top" rowspan="1" colspan="1">2.70</td><td align="center" valign="top" rowspan="1" colspan="1">8.92 (6.20&#x02013;12.62)</td><td align="center" valign="top" rowspan="1" colspan="1">472, 3.62, (1.29&#x02013;9.08)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">van Duynhoven, Genitourin Med., 1997</td><td align="center" valign="top" rowspan="1" colspan="1">Netherlands</td><td align="left" valign="top" rowspan="1" colspan="1">STI clinic at University Hospital of
Rotterdam</td><td align="left" valign="top" rowspan="1" colspan="1">Fair</td><td align="left" valign="top" rowspan="1" colspan="1">STD clinic clients</td><td align="center" valign="top" rowspan="1" colspan="1">Past STIs</td><td align="center" valign="top" rowspan="1" colspan="1">1.10</td><td align="center" valign="top" rowspan="1" colspan="1">2.72 (1.95&#x02013;3.80)</td><td align="center" valign="top" rowspan="1" colspan="1">2876, 2.46, (1.39&#x02013;4.33)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Weinbaum, Am J Public Health, 2008</td><td align="center" valign="top" rowspan="1" colspan="1">USA</td><td align="left" valign="top" rowspan="1" colspan="1">MSM-identified venues: Balt, Dallas, L.A.,
Miami, NYC, S.F., Seattle</td><td align="left" valign="top" rowspan="1" colspan="1">Good</td><td align="left" valign="top" rowspan="1" colspan="1">MSM</td><td align="center" valign="top" rowspan="1" colspan="1">Current STIs</td><td align="center" valign="top" rowspan="1" colspan="1">16.00</td><td align="center" valign="top" rowspan="1" colspan="1">33.20 (27.40&#x02013;39)</td><td align="center" valign="top" rowspan="1" colspan="1">2824, 1.66, (1.46&#x02013;1.96)</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Zou, Transfusion, 2009</td><td rowspan="2" align="center" valign="top" colspan="1">USA</td><td rowspan="2" align="left" valign="top" colspan="1">Blood donation sites</td><td rowspan="2" align="left" valign="top" colspan="1">Fair</td><td align="left" valign="top" rowspan="1" colspan="1">First time blood donors</td><td rowspan="2" align="center" valign="top" colspan="1">Current syphilis</td><td align="center" valign="top" rowspan="1" colspan="1">0.05</td><td align="center" valign="top" rowspan="1" colspan="1">0.91 (0.6&#x02013;1.37)</td><td align="center" valign="top" rowspan="1" colspan="1">1203, 16.66, (11.08&#x02013;24.97)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Repeat blood donors</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">1.17 (0.78&#x02013;1.75)</td><td align="center" valign="top" rowspan="1" colspan="1">155, 117.72, (16.57&#x02013;947)</td></tr></tbody><tbody><tr><td colspan="8" align="left" valign="top" rowspan="1">&#x02003;<bold><italic>B. Studies
using core antibody (anti-Hbc) as HBV
marker</italic></bold></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">
<bold>Author, Pub., Year</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>Country</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>Setting</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>Quality rating</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>Population</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>STI measure</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>Hepatitis B prevalence in
STI-negatives</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>Prevalence
ratios</bold><sup>1</sup><break/>N, point est., (Low-High 95% CI)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bratos, Sex Transm Dis., 1993</td><td align="center" valign="top" rowspan="1" colspan="1">Spain</td><td align="left" valign="top" rowspan="1" colspan="1">Public health clinic</td><td align="left" valign="top" rowspan="1" colspan="1">Fair</td><td align="left" valign="top" rowspan="1" colspan="1">Female prostitutes</td><td align="center" valign="top" rowspan="1" colspan="1">Current syphilis</td><td align="center" valign="top" rowspan="1" colspan="1">9.70</td><td align="center" valign="top" rowspan="1" colspan="1">127, 2.54, (1.06&#x02013;6.08)</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Carmo, Gen Hosp Psychiatry,
2014</td><td rowspan="2" align="center" valign="top" colspan="1">Brazil</td><td rowspan="2" align="left" valign="top" colspan="1">26 public mental health
services</td><td rowspan="2" align="left" valign="top" colspan="1">Fair</td><td rowspan="2" align="left" valign="top" colspan="1">Randomly selected adults with
mental illness under care</td><td align="center" valign="top" rowspan="1" colspan="1">Past STIs</td><td align="center" valign="top" rowspan="1" colspan="1">15.70</td><td align="center" valign="top" rowspan="1" colspan="1">2176, 1.20, (1.07&#x02013;1.33)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Past syphilis</td><td align="center" valign="top" rowspan="1" colspan="1">16.20</td><td align="center" valign="top" rowspan="1" colspan="1">2140, 1.29, (1.05&#x02013;1.58)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Carvalho. Cad Saude Publica, 2017</td><td align="center" valign="top" rowspan="1" colspan="1">Brazil</td><td align="left" valign="top" rowspan="1" colspan="1">Public shelter in city<break/>of
Goi&#x000e2;nia</td><td align="left" valign="top" rowspan="1" colspan="1">Fair</td><td align="left" valign="top" rowspan="1" colspan="1">Persons experiencing homelessness</td><td align="center" valign="top" rowspan="1" colspan="1">Past STIs</td><td align="center" valign="top" rowspan="1" colspan="1">15.50</td><td align="center" valign="top" rowspan="1" colspan="1">271, 1.13, (0.83&#x02013;1.60)</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Corona, Epidemiol Infect.,
1991</td><td rowspan="2" align="center" valign="top" colspan="1">Italy</td><td rowspan="2" align="left" valign="top" colspan="1">STI clinic in Rome</td><td rowspan="2" align="left" valign="top" colspan="1">Fair</td><td align="left" valign="top" rowspan="1" colspan="1">Consecutive outpatients - non-PWID
heterosexuals</td><td rowspan="2" align="center" valign="top" colspan="1">Past STIs</td><td align="center" valign="top" rowspan="1" colspan="1">21.10</td><td align="center" valign="top" rowspan="1" colspan="1">1136, 1.56, (1.28&#x02013;1.86)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Consecutive outpatients - non-PWID
homosexuals</td><td align="center" valign="top" rowspan="1" colspan="1">50.00</td><td align="center" valign="top" rowspan="1" colspan="1">196, 1.25, (0.92&#x02013;1.54)</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Corona, J Med Virol., 1996</td><td rowspan="2" align="center" valign="top" colspan="1">Italy</td><td rowspan="2" align="left" valign="top" colspan="1">STI clinic in Rome</td><td rowspan="2" align="left" valign="top" colspan="1">Good</td><td rowspan="2" align="left" valign="top" colspan="1">Non-PWID heterosexuals</td><td align="center" valign="top" rowspan="1" colspan="1">Past chlamydia / gonorrhea</td><td align="center" valign="top" rowspan="1" colspan="1">18.10</td><td align="center" valign="top" rowspan="1" colspan="1">1497, 0.98, (0.73&#x02013;1.27)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Current syphilis</td><td align="center" valign="top" rowspan="1" colspan="1">13.00</td><td align="center" valign="top" rowspan="1" colspan="1">1497, 2.01, (1.51&#x02013;2.59)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Deininger, Klin Wochenschr., 1990</td><td align="center" valign="top" rowspan="1" colspan="1">Germany</td><td align="left" valign="top" rowspan="1" colspan="1">HIV Clinic</td><td align="left" valign="top" rowspan="1" colspan="1">Fair</td><td align="left" valign="top" rowspan="1" colspan="1">Gay and bisexual men</td><td align="center" valign="top" rowspan="1" colspan="1">Past syphilis</td><td align="center" valign="top" rowspan="1" colspan="1">52.30</td><td align="center" valign="top" rowspan="1" colspan="1">1961, 2.00, (1.80&#x02013;2.13)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fiscus, Sex Transm Dis.,1994</td><td align="center" valign="top" rowspan="1" colspan="1">USA</td><td align="left" valign="top" rowspan="1" colspan="1">STI clinics; three counties in N.
Carolina</td><td align="left" valign="top" rowspan="1" colspan="1">Fair</td><td align="left" valign="top" rowspan="1" colspan="1">STD clinic clients tested for syphilis</td><td align="center" valign="top" rowspan="1" colspan="1">Current syphilis</td><td align="center" valign="top" rowspan="1" colspan="1">5.60</td><td align="center" valign="top" rowspan="1" colspan="1">139, 1.50, (1.10&#x02013;2.10)</td></tr><tr><td rowspan="3" align="left" valign="top" colspan="1">Gilson, Sex Transm Infect.,
1998</td><td rowspan="3" align="center" valign="top" colspan="1">United Kingdom</td><td rowspan="3" align="left" valign="top" colspan="1">Open access GUM clinic in central
London</td><td rowspan="3" align="left" valign="top" colspan="1">Fair</td><td align="left" valign="top" rowspan="1" colspan="1">HIV-neg homosexual men</td><td rowspan="3" align="center" valign="top" colspan="1">Past STIs<break/>&#x0003e;2 vs
&#x0003c;2 lifetime episodes</td><td align="center" valign="top" rowspan="1" colspan="1">28.90</td><td align="center" valign="top" rowspan="1" colspan="1">441, 5.19, (3.38&#x02013;7.65)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HIV-neg heterosexual men</td><td align="center" valign="top" rowspan="1" colspan="1">6.30</td><td align="center" valign="top" rowspan="1" colspan="1">527, 0.94, (0.38&#x02013;2.27)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HIV-neg women</td><td align="center" valign="top" rowspan="1" colspan="1">4.60</td><td align="center" valign="top" rowspan="1" colspan="1">821, 1.00, (0.03&#x02013;2.66)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hakre, Sex Transm Infect., 2013</td><td align="center" valign="top" rowspan="1" colspan="1">Panama</td><td align="left" valign="top" rowspan="1" colspan="1">Venues for registered and
unregistered<break/>FSWs in 8 Provinces</td><td align="left" valign="top" rowspan="1" colspan="1">Good</td><td align="left" valign="top" rowspan="1" colspan="1">FSWs</td><td align="center" valign="top" rowspan="1" colspan="1">Current syphilis</td><td align="center" valign="top" rowspan="1" colspan="1">8.00</td><td align="center" valign="top" rowspan="1" colspan="1">38, 2.21, (1.10&#x02013;4.46)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hawkins, J Infect Dis.,1992</td><td align="center" valign="top" rowspan="1" colspan="1">USA (see &#x0201c;Setting&#x0201d;)</td><td align="left" valign="top" rowspan="1" colspan="1">Six US Navy ships on deployment to S. America,
W. Africa &#x00026; Mediterranean</td><td align="left" valign="top" rowspan="1" colspan="1">Good</td><td align="left" valign="top" rowspan="1" colspan="1">Crew members and Marine Corp personnel</td><td align="center" valign="top" rowspan="1" colspan="1">Past STIs</td><td align="center" valign="top" rowspan="1" colspan="1">3.70</td><td align="center" valign="top" rowspan="1" colspan="1">2071, 1.84, (1.10&#x02013;4.21)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hennessey, J Urban Health, 2009</td><td align="center" valign="top" rowspan="1" colspan="1">USA</td><td align="left" valign="top" rowspan="1" colspan="1">Jail - Chicago, Detroit, San Francisco</td><td align="left" valign="top" rowspan="1" colspan="1">Fair</td><td align="left" valign="top" rowspan="1" colspan="1">Incoming jail inmates (M + F)</td><td align="center" valign="top" rowspan="1" colspan="1">Current syphilis</td><td align="center" valign="top" rowspan="1" colspan="1">16.00</td><td align="center" valign="top" rowspan="1" colspan="1">11166, 1.80, (1.50&#x02013;2.14)</td></tr></tbody><tbody><tr><td colspan="8" align="left" valign="top" rowspan="1">&#x02003;<bold><italic>C. Studies
using core antibody (anti-Hbc) as HBV
marker</italic></bold></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">
<bold>Author, Pub., Year</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>Country</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>Setting</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>Quality rating</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>Population</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>STI measure</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>Hepatitis B prevalence in
STI-negatives</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>Prevalence ratios</bold><break/>N,
point est., (Low-High 95% CI)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Juarez-Figueroa, Sex Transm Infect., 1998</td><td align="center" valign="top" rowspan="1" colspan="1">Mexico</td><td align="left" valign="top" rowspan="1" colspan="1">Centre for HIV/STI detection in FSWs</td><td align="left" valign="top" rowspan="1" colspan="1">Fair</td><td align="left" valign="top" rowspan="1" colspan="1">FSWs</td><td align="center" valign="top" rowspan="1" colspan="1">Current syphilis</td><td align="center" valign="top" rowspan="1" colspan="1">5.80</td><td align="center" valign="top" rowspan="1" colspan="1">1498, 1.81, (0.91&#x02013;3.06)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mele, Eur J Epidemiol., 1988</td><td align="center" valign="top" rowspan="1" colspan="1">Italy</td><td align="left" valign="top" rowspan="1" colspan="1">STI clinic</td><td align="left" valign="top" rowspan="1" colspan="1">Fair</td><td align="left" valign="top" rowspan="1" colspan="1">STD clinic clients, male; heterosexual &#x00026;
gay/bisexual</td><td align="center" valign="top" rowspan="1" colspan="1">Past STIs</td><td align="center" valign="top" rowspan="1" colspan="1">46.40</td><td align="center" valign="top" rowspan="1" colspan="1">913, 1.32, (1.15&#x02013;1.58)</td></tr><tr><td rowspan="3" align="left" valign="top" colspan="1">Oliveira, Mem Inst Oswaldo Cruz,
2001</td><td rowspan="3" align="center" valign="top" colspan="1">Brazil</td><td rowspan="3" align="left" valign="top" colspan="1">STI Clinic, Universidade Federal
Fluminense, State of Rio de Janeiro</td><td rowspan="3" align="left" valign="top" colspan="1">Fair</td><td rowspan="3" align="left" valign="top" colspan="1">STD clinic clients</td><td align="center" valign="top" rowspan="1" colspan="1">Current syphilis</td><td align="center" valign="top" rowspan="1" colspan="1">11.60</td><td align="center" valign="top" rowspan="1" colspan="1">440, 1.80, (1.03&#x02013;3.54)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Past STIs</td><td align="center" valign="top" rowspan="1" colspan="1">12.60</td><td align="center" valign="top" rowspan="1" colspan="1">433, 1.12, (0.68&#x02013;1.85)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Clinic STI history</td><td align="center" valign="top" rowspan="1" colspan="1">9.50</td><td align="center" valign="top" rowspan="1" colspan="1">440, 1.50, (0.82&#x02013;2.75)</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Ribeiro, Int J Environ Res Public
Health, 2017</td><td rowspan="2" align="center" valign="top" colspan="1">Brazil</td><td rowspan="2" align="left" valign="top" colspan="1">Private hemodialysis clinic &#x00026;
public hematology center, Fortaleza, Brazil</td><td rowspan="2" align="left" valign="top" colspan="1">Fair</td><td align="left" valign="top" rowspan="1" colspan="1">Male &#x00026; female pts with chronic renal
failure</td><td rowspan="2" align="center" valign="top" colspan="1">Past STIs</td><td align="center" valign="top" rowspan="1" colspan="1">54.90</td><td align="center" valign="top" rowspan="1" colspan="1">141, 1.07, (0.78&#x02013;1.47)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Male and female pts with coagulapathy</td><td align="center" valign="top" rowspan="1" colspan="1">20.00</td><td align="center" valign="top" rowspan="1" colspan="1">50, 4.00, (2.00&#x02013;8.00)</td></tr><tr><td rowspan="9" align="left" valign="top" colspan="1">Tien, Clin Infect Dis., 2004</td><td rowspan="9" align="center" valign="top" colspan="1">USA</td><td rowspan="9" align="left" valign="top" colspan="1">At home or work</td><td rowspan="9" align="left" valign="top" colspan="1">Fair</td><td rowspan="2" align="left" valign="top" colspan="1">Females at risk of HIV - PWID</td><td rowspan="6" align="center" valign="top" colspan="1">Past gonorrhea<break/>Past
chlamydia</td><td rowspan="2" align="center" valign="top" colspan="1">76.00</td><td align="center" valign="top" rowspan="1" colspan="1">581, 1.06, (0.97&#x02013;1.16)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">581, 1.03, (0.89&#x02013;1.13)</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Females at risk of HIV -
non-PWID</td><td rowspan="2" align="center" valign="top" colspan="1">30.00</td><td align="center" valign="top" rowspan="1" colspan="1">512, 1.46, (1.15&#x02013;1.85)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">512, 1.67, (1.23&#x02013;2.26)</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Females at risk of HIV - no
illicit drug use</td><td rowspan="2" align="center" valign="top" colspan="1">17.00</td><td align="center" valign="top" rowspan="1" colspan="1">850, 1.25, (0.84&#x02013;1.87)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">850, 0.88, (0.42&#x02013;1.83)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Females at risk of HIV - PWID</td><td rowspan="3" align="center" valign="top" colspan="1">Past syphilis</td><td rowspan="3" align="center" valign="top" colspan="1">76.00</td><td align="center" valign="top" rowspan="1" colspan="1">581, 1.07, (0.90&#x02013;1.18)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Females at risk of HIV - non-PWID</td><td align="center" valign="top" rowspan="1" colspan="1">512, 1.18, (1.08&#x02013;1.24)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Females at risk of HIV - no illicit drug
use</td><td align="center" valign="top" rowspan="1" colspan="1">850, 1.11, (0.95&#x02013;1.21)</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Trepka, Sex Transm Dis, 2003</td><td rowspan="2" align="center" valign="top" colspan="1">USA</td><td rowspan="2" align="left" valign="top" colspan="1">Large public STI clinic</td><td rowspan="2" align="left" valign="top" colspan="1">Fair</td><td align="left" valign="top" rowspan="1" colspan="1">Male clinic clients 18+ yo</td><td rowspan="2" align="center" valign="top" colspan="1">Past STIs</td><td align="center" valign="top" rowspan="1" colspan="1">20.00</td><td align="center" valign="top" rowspan="1" colspan="1">376, 2.32, (1.63&#x02013;3.30)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Female clinic clients 18+ yo</td><td align="center" valign="top" rowspan="1" colspan="1">16.00</td><td align="center" valign="top" rowspan="1" colspan="1">242, 1.59, (1.00&#x02013;2.63)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">van Duynhoven, Genitourin Med., 1997</td><td align="center" valign="top" rowspan="1" colspan="1">Netherlands</td><td align="left" valign="top" rowspan="1" colspan="1">STI clinic at University Hospital of
Rotterdam</td><td align="left" valign="top" rowspan="1" colspan="1">Fair</td><td align="left" valign="top" rowspan="1" colspan="1">STD clinic clients</td><td align="center" valign="top" rowspan="1" colspan="1">Past STIs</td><td align="center" valign="top" rowspan="1" colspan="1">12.90</td><td align="center" valign="top" rowspan="1" colspan="1">2848, 1.33, (1.09&#x02013;1.56)</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Weinstock, JAMA., 1993</td><td rowspan="2" align="center" valign="top" colspan="1">USA</td><td rowspan="2" align="left" valign="top" colspan="1">Public STI Clinic; San
Francisco</td><td rowspan="2" align="left" valign="top" colspan="1">Fair</td><td rowspan="2" align="left" valign="top" colspan="1">Patients with new problem and
routine screening for syphilis</td><td align="center" valign="top" rowspan="1" colspan="1">Past gonorrhea</td><td align="center" valign="top" rowspan="1" colspan="1">18.80</td><td align="center" valign="top" rowspan="1" colspan="1">1159, 2.30, (1.95&#x02013;2.68)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Past syphilis</td><td align="center" valign="top" rowspan="1" colspan="1">24.40</td><td align="center" valign="top" rowspan="1" colspan="1">1155, 2.72, (2.33&#x02013;3.06)</td></tr></tbody><tbody><tr><td colspan="8" align="left" valign="top" rowspan="1">&#x02003;<bold><italic>D. Studies
using either surface (HBsAg) or core (anti-HBc) HBV
markers</italic></bold></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">
<bold>Authors</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>Country</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>Setting</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>Quality rating</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>Population</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>STI measure</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>Hepatitis B prevalence in
STI-negatives</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>Prevalence
ratios</bold><sup>1</sup><break/>N, point est., (Low-High 95% CI)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Baddour, Sex Transm Dis, 1988</td><td align="center" valign="top" rowspan="1" colspan="1">USA</td><td align="left" valign="top" rowspan="1" colspan="1">STI clinic</td><td align="left" valign="top" rowspan="1" colspan="1">Fair</td><td align="left" valign="top" rowspan="1" colspan="1">African American females</td><td align="center" valign="top" rowspan="1" colspan="1">Past STIs</td><td align="center" valign="top" rowspan="1" colspan="1">8.60</td><td align="center" valign="top" rowspan="1" colspan="1">136, 2.83, (1.12&#x02013;7.12)</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Barrett, Sex Transm Dis, 1992</td><td rowspan="2" align="center" valign="top" colspan="1">USA</td><td rowspan="2" align="left" valign="top" colspan="1">STI Clinic Jefferson Cty Dept. of
Health; Birmingham, Ala.</td><td rowspan="2" align="left" valign="top" colspan="1">Fair</td><td rowspan="2" align="left" valign="top" colspan="1">Women 19 y.o.+; not pregnant and
planning to use contraception for trial period</td><td align="center" valign="top" rowspan="1" colspan="1">Current gon. / chlamydia 0.01 &#x02013; 0.23
STIs</td><td rowspan="2" align="center" valign="top" colspan="1">14.00</td><td align="center" valign="top" rowspan="1" colspan="1">557, 0.91, (0.54&#x02013;1.48)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Current gon. / chlamydia 0.24 &#x02013; 1.00
STIs</td><td align="center" valign="top" rowspan="1" colspan="1">557, 1.33, (0.82&#x02013;2.07)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">El Maerrawi, International J STD AIDS,
2015</td><td align="center" valign="top" rowspan="1" colspan="1">Brazil</td><td align="left" valign="top" rowspan="1" colspan="1">Sao Paulo prison for men</td><td align="left" valign="top" rowspan="1" colspan="1">Fair</td><td align="left" valign="top" rowspan="1" colspan="1">Sao Paulo prison for men; all inmates were
included</td><td align="center" valign="top" rowspan="1" colspan="1">Past STIs</td><td align="center" valign="top" rowspan="1" colspan="1">21.00</td><td align="center" valign="top" rowspan="1" colspan="1">21, 1.81, (1.15&#x02013;2.57)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hwang, Clin Infect Dis, 2000</td><td align="center" valign="top" rowspan="1" colspan="1">USA</td><td align="left" valign="top" rowspan="1" colspan="1">Two drug treatment clinics in Houston &#x00026;
drug treatment clinic in Lubbock, Texas</td><td align="left" valign="top" rowspan="1" colspan="1">Good</td><td align="left" valign="top" rowspan="1" colspan="1">Indigent residents addicted to drugs and
alcohol</td><td align="center" valign="top" rowspan="1" colspan="1">Past STIs</td><td align="center" valign="top" rowspan="1" colspan="1">22.40</td><td align="center" valign="top" rowspan="1" colspan="1">407, 1.41, (0.84&#x02013;2.07)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lama, Am J Trop Med Hyg, 2010</td><td align="center" valign="top" rowspan="1" colspan="1">Peru</td><td align="left" valign="top" rowspan="1" colspan="1">Sentinel surveillance survey in 6 HBV-endemic
cities</td><td align="left" valign="top" rowspan="1" colspan="1">Fair</td><td align="left" valign="top" rowspan="1" colspan="1">Men 18+ y.o. and had sexual intercourse with
1+ men during previous year</td><td align="center" valign="top" rowspan="1" colspan="1">Current syphilis</td><td align="center" valign="top" rowspan="1" colspan="1">25.50</td><td align="center" valign="top" rowspan="1" colspan="1">354, 1.46, (1.21&#x02013;1.74)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Levine, Am J Epi, 1995</td><td align="center" valign="top" rowspan="1" colspan="1">USA</td><td align="left" valign="top" rowspan="1" colspan="1">Baltimore; extensive community outreach</td><td align="left" valign="top" rowspan="1" colspan="1">Fair</td><td align="left" valign="top" rowspan="1" colspan="1">Former and current IV drug users who were
subjects of ALIVE HIV longitudinal study</td><td align="center" valign="top" rowspan="1" colspan="1">Past syphilis</td><td align="center" valign="top" rowspan="1" colspan="1">83.50</td><td align="center" valign="top" rowspan="1" colspan="1">2193, 1.02, (0.97&#x02013;1.08)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Matos, Sex Transm Infect, 2008</td><td align="center" valign="top" rowspan="1" colspan="1">Brazil</td><td align="left" valign="top" rowspan="1" colspan="1">Highway through Goiania City</td><td align="left" valign="top" rowspan="1" colspan="1">Good</td><td align="left" valign="top" rowspan="1" colspan="1">Truck drivers</td><td align="center" valign="top" rowspan="1" colspan="1">Past STIs</td><td align="center" valign="top" rowspan="1" colspan="1">14.60</td><td align="center" valign="top" rowspan="1" colspan="1">615, 1.78, (1.05&#x02013;3.00)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Moura, International J Inf Dis, 2015</td><td align="center" valign="top" rowspan="1" colspan="1">Brazil</td><td align="left" valign="top" rowspan="1" colspan="1">Maceio, capital of State of Alagoas, Municipal
Health Office</td><td align="left" valign="top" rowspan="1" colspan="1">Fair</td><td align="left" valign="top" rowspan="1" colspan="1">Pregnant women</td><td align="center" valign="top" rowspan="1" colspan="1">Current syphilis</td><td align="center" valign="top" rowspan="1" colspan="1">0.40</td><td align="center" valign="top" rowspan="1" colspan="1">54729, 0.81, (0.33&#x02013;1.97)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Oliveira, PLOS One, 2016</td><td align="center" valign="top" rowspan="1" colspan="1">Brazil</td><td align="left" valign="top" rowspan="1" colspan="1">MSM in City of Goiania</td><td align="left" valign="top" rowspan="1" colspan="1">Fair</td><td align="left" valign="top" rowspan="1" colspan="1">MSM recruited using Respondent-Driven
Sampling</td><td align="center" valign="top" rowspan="1" colspan="1">Past STIs</td><td align="center" valign="top" rowspan="1" colspan="1">15.40</td><td align="center" valign="top" rowspan="1" colspan="1">522, 3.33, (1.83&#x02013;4.80)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pando, Sex Transm Dis, 2006</td><td align="center" valign="top" rowspan="1" colspan="1">Argentina</td><td align="left" valign="top" rowspan="1" colspan="1">Recruitment from gay nightclubs, porn cinemas,
gyms, and streets</td><td align="left" valign="top" rowspan="1" colspan="1">Fair</td><td align="left" valign="top" rowspan="1" colspan="1">MSM</td><td align="center" valign="top" rowspan="1" colspan="1">Past STIs</td><td align="center" valign="top" rowspan="1" colspan="1">32.40</td><td align="center" valign="top" rowspan="1" colspan="1">694, 1.47, (1.18&#x02013;1.77)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pando, Am J trop Med Hyg, 2006</td><td align="center" valign="top" rowspan="1" colspan="1">Argentina</td><td align="left" valign="top" rowspan="1" colspan="1">FSWs in 6 cities contacted through an NGO</td><td align="left" valign="top" rowspan="1" colspan="1">Fair</td><td align="left" valign="top" rowspan="1" colspan="1">FSWs</td><td align="center" valign="top" rowspan="1" colspan="1">Current syphilis</td><td align="center" valign="top" rowspan="1" colspan="1">14.40</td><td align="center" valign="top" rowspan="1" colspan="1">625, 1.80, (1.25&#x02013;2.64)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pando, J Med Micro, 2008</td><td align="center" valign="top" rowspan="1" colspan="1">Argentina</td><td align="left" valign="top" rowspan="1" colspan="1">Three public hospitals in Buenos Aires</td><td align="left" valign="top" rowspan="1" colspan="1">Fair</td><td align="left" valign="top" rowspan="1" colspan="1">TB patients &#x0003e; 18 years old</td><td align="center" valign="top" rowspan="1" colspan="1">Past STIs</td><td align="center" valign="top" rowspan="1" colspan="1">11.6%</td><td align="center" valign="top" rowspan="1" colspan="1">181, 2.3 (1.2&#x02013;4.7)</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Remis, Am J Pub Health, 2000</td><td rowspan="2" align="center" valign="top" colspan="1">Canada</td><td rowspan="2" align="left" valign="top" colspan="1">Clinic and community settings</td><td rowspan="2" align="left" valign="top" colspan="1">Fair</td><td rowspan="2" align="left" valign="top" colspan="1">HIV-neg MSM</td><td align="center" valign="top" rowspan="1" colspan="1">Past STIs</td><td rowspan="2" align="center" valign="top" colspan="1">40.9%</td><td align="center" valign="top" rowspan="1" colspan="1">328, 2.14 (1.57&#x02013;2.39)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Past gonorrhea or chlamydia</td><td align="center" valign="top" rowspan="1" colspan="1">328, 1.80 (1.38&#x02013;2.11)</td></tr><tr><td rowspan="3" align="left" valign="top" colspan="1">Rosenblum, J Infect Dis, 1990</td><td rowspan="3" align="center" valign="top" colspan="1">USA</td><td rowspan="3" align="left" valign="top" colspan="1">Belle Glade, Florida</td><td rowspan="3" align="left" valign="top" colspan="1">Fair</td><td rowspan="3" align="left" valign="top" colspan="1">Adults from randomly selected
households</td><td align="center" valign="top" rowspan="1" colspan="1">Current syphilis</td><td align="center" valign="top" rowspan="1" colspan="1">21.0%</td><td align="center" valign="top" rowspan="1" colspan="1">723, 2.05 (2.00&#x02013;4.80)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Past syphilis</td><td align="center" valign="top" rowspan="1" colspan="1">29.0%</td><td align="center" valign="top" rowspan="1" colspan="1">714, 1.64 (1.16&#x02013;2.32)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Past gonorrhea</td><td align="center" valign="top" rowspan="1" colspan="1">26.0%</td><td align="center" valign="top" rowspan="1" colspan="1">712, 1.65 (1.32&#x02013;2.06)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rosenblum, JAMA, 1992</td><td align="center" valign="top" rowspan="1" colspan="1">USA</td><td align="left" valign="top" rowspan="1" colspan="1">Detention centers in Miami and L.A., brothels
in NV, STI clinics in CO, drug Tx programs in NJ, street / social
network outreach in Atlanta, NJ, and S.F.</td><td align="left" valign="top" rowspan="1" colspan="1">Fair</td><td align="left" valign="top" rowspan="1" colspan="1">Women 18 years old+ who had exchanged sexual
services for money or drugs at least once since 1978</td><td align="center" valign="top" rowspan="1" colspan="1">Past syphilis</td><td align="center" valign="top" rowspan="1" colspan="1">70.0%</td><td align="center" valign="top" rowspan="1" colspan="1">646, 2.7 (1.9&#x02013;4.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Seage, Pub Health Rep, 1997</td><td align="center" valign="top" rowspan="1" colspan="1">USA</td><td align="left" valign="top" rowspan="1" colspan="1">Student participants recruited via outreach at
colleges. Other participants recruited from Fenway Community Health
Center, and gay nightclubs</td><td align="left" valign="top" rowspan="1" colspan="1">Fair</td><td align="left" valign="top" rowspan="1" colspan="1">MSM enrolled in college in Boston area and
younger than 30 or, if not students, 18 to 24 years old.</td><td align="center" valign="top" rowspan="1" colspan="1">Past STIs</td><td align="center" valign="top" rowspan="1" colspan="1">11.7%</td><td align="center" valign="top" rowspan="1" colspan="1">317, 3.11 (1.11&#x02013;8.76)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Segura, AIDS Care, 2010</td><td align="center" valign="top" rowspan="1" colspan="1">Argentina</td><td align="left" valign="top" rowspan="1" colspan="1">NGO clinic</td><td align="left" valign="top" rowspan="1" colspan="1">Fair</td><td align="left" valign="top" rowspan="1" colspan="1">MSM</td><td align="center" valign="top" rowspan="1" colspan="1">Current syphilis</td><td align="center" valign="top" rowspan="1" colspan="1">25.0%</td><td align="center" valign="top" rowspan="1" colspan="1">811, 2.40 (1.50&#x02013;3.11)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Zocratto, Sub Use Misuse, 2010</td><td align="center" valign="top" rowspan="1" colspan="1">Argentina and Uruguay</td><td align="left" valign="top" rowspan="1" colspan="1">Outreached clients recruited by civil
associations. Hospitalized or outpatients recruited from 2 public and 1
nonpublic hospital for drug user and psychiatric diseases</td><td align="left" valign="top" rowspan="1" colspan="1">Fair</td><td align="left" valign="top" rowspan="1" colspan="1">Out-of-treatment and in-treatment
Non-Injecting Cocaine Users from low-income neighborhoods in Montevideo
and Buenos Aires.</td><td align="center" valign="top" rowspan="1" colspan="1">Current syphilis</td><td align="center" valign="top" rowspan="1" colspan="1">10.8%</td><td align="center" valign="top" rowspan="1" colspan="1">89, 3.62 (2.16&#x02013;5.33)</td></tr></tbody></table></table-wrap><table-wrap id="T2" position="float" orientation="landscape"><label>Table 2.</label><caption><p id="P48">Summary of evidence for the association of HBV infection with STIs</p></caption><table frame="box" rules="all"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" valign="top" rowspan="1" colspan="1">Outcome</th><th align="center" valign="top" rowspan="1" colspan="1">Number of data points</th><th align="center" valign="top" rowspan="1" colspan="1">Prevalence Ratio (95% CI); pooled if
&#x02265;2 studies</th><th align="center" valign="top" rowspan="1" colspan="1">I<sup>2</sup> (Q test p-value)</th><th align="center" valign="top" rowspan="1" colspan="1">References (distinguishing characteristic
for studies with &#x0003e;1 outcome)</th></tr></thead><tbody><tr><td colspan="5" align="left" valign="top" rowspan="1">
<bold>HBV surface antigen (HBsAg
)</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Syphilis &#x02013; Current</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>6.76
(2.10&#x02013;21.76)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>91.4% (0.00)</bold>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Hennessey 2009; Miranda 2001; Parazzini
1992 (TPHA); Parazzini 1992 (VDRL); Zou 2009 (First-time donors); Zou
2009 (Repeat donors)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Syphilis &#x02013; Past</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>2.36 (1.36&#x02013;4.08)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">N/A</td><td align="left" valign="middle" rowspan="1" colspan="1">Carmo 2014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Chlamydia / gonorrhea &#x02013;
Current</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">2.0 (0.93&#x02013;4.32)</td><td align="center" valign="middle" rowspan="1" colspan="1">N/A</td><td align="left" valign="middle" rowspan="1" colspan="1">Hart 1992</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Unspecified STIs &#x02013;
Past</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>1.65 (1.08&#x02013;2.52)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>73.6% (0.004)</bold>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Carmo 2014; Miranda 2001; Souto 2001; van
Duynhoven 1997; Weinbaum 2008</td></tr><tr><td colspan="5" align="left" valign="middle" rowspan="1">
<bold>HBV core antibodies
(anti-HBc)</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Syphilis &#x02013; Current</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>1.82 (1.60&#x02013;
2.06)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>84.0%; (0.00)</bold>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Bratos 1993; Corona 1993; Fiscus 1994;
Hakre 2013; Hennessey 2009; Juarez-Figueroa 1998; Oliviera 2001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Syphilis &#x02013; Past</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>1.48 (1.10&#x02013;1.99)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>97.6%; (0.00)</bold>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Carmo 2014; Deininger 1990; Tien 2004
(PWID); Tien 2004 (No illicit drugs); Tien 2004 (Non- PWID); Weinstock
1993</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Chlamydia / gonorrhea &#x02013;
Past</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>1.30 (1.02&#x02013;1.66)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>92.3%; (0.00)</bold>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Corona 1996; Tien 2004 (No illicit drug);
Tien 2004 (Chlamydia, PWID); Tien 2004 (Chlamydia, No illicit drug);
Tien 2004 (Chlamydia, non-PWID); Tien 2004 (Gonorrhea, PWID); Tien 2004
(Gonorrhea, non-PWID); Weinstock 1993</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Unspecified STIs &#x02013;
Current</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>1.42 (1.23&#x02013;1.63)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>42.4% (0.00)</bold>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Corona 1991 (non-IDU heterosex).; Corona
1991 (non-IDU homosex.); Oliviera 2001; Oliviera 2001 clinic</td></tr><tr><td colspan="5" align="left" valign="middle" rowspan="1">
<bold>HBsAg or anti-HBc;
combined</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Syphilis &#x02013; Current</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>1.69 ( 1.39&#x02013;2.07</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>96.1% (0.00)</bold>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Lama 2010; Moura 2015; Pando 2006;
Rosenblum 1990; Rosenblum 1992; Segura 2010; Zocratto 2010</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Syphilis &#x02013; Past</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">1.51 (0.89&#x02013;1.52)</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>95.0% (0.00)</bold>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Levine 1995; Remis 2000; Rosenblum
1990</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Chlamydia / gonorrhea &#x02013;
Current</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">1.15 (0.77&#x02013;1.62)</td><td align="center" valign="middle" rowspan="1" colspan="1">15.3% (0.28)</td><td align="left" valign="middle" rowspan="1" colspan="1">Barrett 1992 (more STIs); Barrett 1992
(fewer STIs)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Chlamydia / gonorrhea &#x02013;
Past</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>1.73 (1.48&#x02013;2.01)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0% (0.58)</td><td align="left" valign="middle" rowspan="1" colspan="1">Remis 2000; Rosenblum 1990</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Unspecified STIs &#x02013;
Past</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>1.89 (1.52&#x02013;2.37)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">45.1% (0.08)</td><td align="left" valign="middle" rowspan="1" colspan="1">Baddour 1988; El Maerrawi 2005; Hwang 2000;
Matos 2008; Oliveira 2015; Pando 2006; Pando 2008; Seage 1997</td></tr></tbody></table></table-wrap></floats-group></article>